52
Participants
Start Date
June 10, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
January 30, 2025
Oleoylethanolamide (OEA)
Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.
Placebo
Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.
The Roskamp Institute, Sarasota
United States Department of Defense
FED
Roskamp Institute Inc.
OTHER